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ene-therapy, the technique of inserting genes
into cells to treat disease, holds promise
for many areas of medicine. For Zhuo-Hua Pan,
Ph.D., professor of anatomy and cell biology in the
School of Medicine, and Sean Ainsworth, founder
of RetroSense Therapeutics LLC, the breakthrough
therapy means restoring vision to millions of people
suffering with incurable blindness.
Pan, along with colleagues at Salus University,
has developed a novel gene-therapy approach for
treating blindness caused by age-related macular
degeneration (AMD) and retinitis pigmentosa (RP) –
disorders that are currently incurable. The treatment
delivers a photoreceptor gene from blue-green algae,
which converts previously non-photosensitive
retinal cells to photosensitive cells. The result is
restored light responses in the retina.
AMD is the leading cause of blindness in people
over 60, affecting more than 8 million people in
the U.S. alone. Worldwide, 500,000 individuals lose
their eyesight annually due to AMD, which is the
result of progressive deterioration of the macula, the
central portion of the retina.
RP is a genetically-determined eye disease
caused by any of 100 different genes. An estimated
100,000 people in the U.S. have RP, which typically
manifests as night blindness and progresses to
tunnel vision and sometimes complete blindness.
Other technologies being developed to restore
vision in patients with AMD and RP include
implanted devices and stem cell technologies.
However, stem cells can cause damage to
surrounding cells and implanted devices are highly
invasive and suffer from poor resolution. Pan’s
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technology holds the potential to restore vision
while avoiding these negative side effects.
Ainsworth licensed the technology from Wayne
State University in an effort to eventually test
the technology in humans. While there is at least
six years of research and testing needed before
anything can be brought to the market, FDA Phase I
tests should begin in early 2012.
With this technology, combined the business
expertise of Ainsworth, a seasoned life sciences
consultant and entrepreneur, Pan is hopeful his
breakthrough treatment is on the fast track to
restoring a vital part of the human experience for
millions of people worldwide.
To learn more about RetroSense, visit:
http://www.retro-sense.com/
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